866-997-4948(US-Canada Toll Free)

Colon Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Feb 2013

Category :

Cancer

No. of Pages : 344 Pages


Global Markets Directs, \'Colon Cancer - Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Colon Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Colon Cancer. 

Colon Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Colon Cancer.
  • A review of the Colon Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Colon Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Colon Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Colon Cancer Overview 12
Therapeutics Development 13
An Overview of Pipeline Products for Colon Cancer 13
Colon Cancer Therapeutics under Development by Companies 15
Colon Cancer Therapeutics under Investigation by Universities/Institutes 23
Late Stage Products 26
Comparative Analysis 26
Mid Clinical Stage Products 27
Comparative Analysis 27
Early Clinical Stage Products 28
Comparative Analysis 28
Discovery and Pre-Clinical Stage Products 29
Comparative Analysis 29
Colon Cancer Therapeutics - Products under Development by Companies 30
Colon Cancer Therapeutics - Products under Investigation by Universities/Institutes 38
Companies Involved in Colon Cancer Therapeutics Development 40
AstraZeneca PLC 40
Eli Lilly and Company 41
Bioniche Life Sciences, Inc. 42
Bioneer Corporation 43
Prolexys Pharmaceuticals, Inc. 44
Bio-Path Holdings, Inc. 45
Histogen, Inc. 46
Geistlich Pharma AG 47
Aphios Corporation 48
Alfacell Corporation 49
Alchemia Limited 50
Enzo Biochem, Inc. 51
AEterna Zentaris Inc. 52
ImmunoCellular Therapeutics, Ltd. 53
Idera Pharmaceuticals, Inc. 54
Lorus Therapeutics Inc 55
Bio-Bridge Science, Inc. 56
Bionomics Limited 57
Cleveland BioLabs, Inc. 58
Compugen Ltd. 59
Patrys Limited 60
Critical Outcome Technologies Inc. 61
Curis, Inc. 62
Cytokinetics, Inc 63
Telik, Inc. 64
Dendreon Corporation 65
Choongwae Pharma Corp 66
Green Cross Corporation 67
Innocell Corporation 68
Sareum Holdings plc 69
Transgene Biotek Ltd 70
Rexahn Pharmaceuticals, Inc. 71
MabVax Therapeutics, Inc. 72
Supratek Pharma Inc. 73
Bionucleon Srl 74
Fusion Antibodies Ltd 75
Actinium Pharmaceuticals, Inc. 76
Multimmune GmbH 77
Nerviano Medical Sciences S.r.l. 78
Med Discovery SA 79
Glycotope GmbH 80
Archemix Corp. 81
Provecs Medical GmbH 82
Coronado Biosciences, Inc. 83
OncoMed Pharmaceuticals, Inc. 84
Azaya Therapeutics, Inc. 85
Deciphera Pharmaceuticals, LLC 86
ProNAi Therapeutics, Inc. 87
Mersana Therapeutics, Inc. 88
Affichem 89
Advenchen Laboratories, LLC 90
Pharminox Limited 91
Viral Genetics, Inc. 92
NovaLead Pharma Pvt. Ltd. 93
Vaccinogen, Inc. 94
Etubics Corporation 95
NewLink Genetics Corporation 96
Cellceutix Corporation 97
TVAX Biomedical, LLC 98
CG Therapeutics, Inc. 99
Tautatis Incorporated 100
Viventia Biotechnologies Inc. 101
Merus B.V. 102
Pique Therapeutics 103
Isofol Medical AB 104
PepTx, Inc. 105
Celtic Pharmaceutical Holdings L.P. 106
Gliknik, Inc. 107
EyeGene, Inc. 108
DEKK-TEC, Inc. 109
ISA Pharmaceuticals B.V. 110
TAU Therapeutics, LLC 111
CytomX, LLC. 112
Colon Cancer - Therapeutics Assessment 113
Assessment by Monotherapy Products 113
Assessment by Combination Products 114
Assessment by Route of Administration 115
Assessment by Molecule Type 117
Drug Profiles 120
IMO-2055 - Drug Profile 120
GSK-923295 - Drug Profile 122
LOR-1284 - Drug Profile 124
IL-17E - Drug Profile 125
LOR-253 - Drug Profile 126
CU-903 - Drug Profile 128
Im-01 - Drug Profile 129
MDRG-01 - Drug Profile 130
ICT-037 - Drug Profile 131
ICT-109 - Drug Profile 132
ATI-1150 - Drug Profile 134
Chk-1 Inhibitor Programme - Drug Profile 135
PRLX-93936 - Drug Profile 136
Drug Targeting Carbonic Anhydrase IX - Drug Profile 138
Drug Targeting Carcinoembryonic Antigen - Drug Profile 139
COTI-2 - Drug Profile 140
XMT-1001 - Drug Profile 141
CGEN-25008 - Drug Profile 143
Mycobacterial Cell Wall-DNA Complex Program - Drug Profile 144
TLK-58747 - Drug Profile 145
TLK-60404 - Drug Profile 146
TLK-60596 - Drug Profile 147
PMX-2058 - Drug Profile 148
VLN-244 - Drug Profile 149
OncoVAX - Drug Profile 150
Kevetrin - Drug Profile 152
BP-100-1.02 - Drug Profile 155
BNC-105 - Drug Profile 156
ATN-658 - Drug Profile 157
PI3K/MEK Inhibitor - Drug Profile 158
demcizumab - Drug Profile 159
PAT-CM1 - Drug Profile 162
RX-0183 - Drug Profile 163
X-379 - Drug Profile 164
aspirin - Drug Profile 165
bevacizumab + [cetuximab] + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 166
AF-122 - Drug Profile 168
cixutumumab + [cetuximab] + [irinotecan hydrochloride hydrochloride] - Drug Profile 169
CG-201 - Drug Profile 170
selumetinib sulfate + [dacarbazine] + [docetaxel] + [erlotinib] +[temsirolimus] - Drug Profile 171
tegafur + uracil + leucovorin - Drug Profile 173
muromonab-CD3 + [aldesleukin] + Autologous Tumor Cell Vaccine + Therapeutic Autologous Lymphocytes - Drug Profile 174
PHA-793887 - Drug Profile 176
rebastinib - Drug Profile 177
Tegafur + Gimeracil + Oteracil Potassium - Drug Profile 179
TTT-3002 - Drug Profile 180
Immuncell-LC - Drug Profile 181
taurolidine - Drug Profile 183
BNC-105-P - Drug Profile 184
CHP-MAGE-A4 Vaccine - Drug Profile 185
peptide cancer vaccine + [basiliximab] - Drug Profile 186
ETBX-011 - Drug Profile 187
Dendritic Cells Pulsed With HLA-A24-Restricted CEA Peptide - Drug Profile 189
AEZS-131 - Drug Profile 190
AEZS-132 - Drug Profile 191
modified vaccinia virus ankara vaccine expressing p53 - Drug Profile 192
SP-1063C - Drug Profile 193
Colon Cancer Vaccine - Drug Profile 194
Irinotecan hydrochloride + Radiation therapy - Drug Profile 195
corticorelin acetate + [bevacizumab] 196
Drug Profile 196
Drugs For Cancer - Drug Profile 198
X-480 - Drug Profile 199
PT-128 - Drug Profile 200
Probodies Program - Drug Profile 201
VB6-011 - Drug Profile 202
VB6-050 - Drug Profile 203
PMX-500 - Drug Profile 204
DPK-M2 - Drug Profile 205
DPK-M1 - Drug Profile 206
TTL-1177 - Drug Profile 207
Modufolin - Drug Profile 208
NLG-8189 + Adenovirus-p53 Transduced Dendritic Cell Vaccine - Drug Profile 209
Aurora Kinases + FLT-3 Kinase Program - Drug Profile 211
OXT-922 - Drug Profile 213
Betulinic Acid - Drug Profile 214
P53-SLP - Drug Profile 215
rhErbB3-f - Drug Profile 217
PNT-200 - Drug Profile 219
PNT-300 - Drug Profile 220
PNT-400 - Drug Profile 221
PNT-500 - Drug Profile 222
PNT-600 - Drug Profile 223
BACPT DP - Drug Profile 224
Project PFKFB-3 - Drug Profile 225
linifanib - Drug Profile 227
PMX-290 - Drug Profile 228
Tetrandrine - Drug Profile 229
Pb-TCMC-Trastuzumab - Drug Profile 230
VXM-01 - Drug Profile 232
r5B1 - Drug Profile 234
COTI-2 + [erlotinib hydrochloride] - Drug Profile 235
COTI-2 + [cetuximab] - Drug Profile 236
rAmphinase-2 - Drug Profile 237
Natural Amphinase-3 - Drug Profile 239
TVI-Colon-1 - Drug Profile 240
Corvlysis - Drug Profile 241
ONS-1035 - Drug Profile 242
CFAKY-15 - Drug Profile 244
MG-1102 - Drug Profile 245
Actimab-C - Drug Profile 246
aspirin - Drug Profile 247
CNDO-109 - Drug Profile 248
Hyaluronic Acid-Camptosar + Erbitux + Avastin - Drug Profile 250
naproxen - Drug Profile 251
Zycan - Drug Profile 252
NO-naproxen - Drug Profile 253
TBL-0306C - Drug Profile 254
BNC-101 - Drug Profile 255
Mobilan - Drug Profile 256
Antimycon - Drug Profile 257
AL-2846 - Drug Profile 258
Human Extracellular Matrix - Drug Profile 259
CG-0070-IT - Drug Profile 260
KaroMab-GEX - Drug Profile 261
EC-8042 - Drug Profile 262
NOV110401 - Drug Profile 263
hydroxychloroquine + sorafenib - Drug Profile 264
PAT-SM4 - Drug Profile 265
PTX-001 - Drug Profile 266
QBECO SSI - Drug Profile 268
EGFR Stratobody - Drug Profile 270
Tumor Metabolism Program - Drug Profile 271
Tumor Metabolism Program TBN - Drug Profile 272
Microtubule Binding Agents Programme - Drug Profile 273
Aplysiatoxin Derivative - Drug Profile 274
P-900 - Drug Profile 275
P-732 - Drug Profile 276
PTX-004 - Drug Profile 277
ARC-127 - Drug Profile 278
MCT-1 Inhibitors - Drug Profile 280
Drugs Targeting Thymidylate Synthase And Dihydrofolate Reductase - Drug Profile 282
BC-2059 - Drug Profile 283
MUC1 Peptide Poly ICLC Adjuvant Vaccine - Drug Profile 284
Imidazoles - Drug Profile 286
DCB-CA1 - Drug Profile 287
GDOX-Related Molecules - Drug Profile 288
OXT-328 - Drug Profile 289
largazole - Drug Profile 290
Drug For Solid Cancers - Drug Profile 291
DT-330 - Drug Profile 292
Thiocoraline - Drug Profile 293
Colon Cancer Therapeutics - Drug Profile Updates 294
Colon Cancer Therapeutics - Discontinued Products 319
Colon Cancer Therapeutics - Dormant Products 321
Colon Cancer - Product Development Milestones 328
Featured News & Press Releases 328

Appendix 333
Methodology 333
Coverage 333
Secondary Research 333
Primary Research 333
Expert Panel Validation 333
Contact Us 334
Disclaimer 334

List of Table


Number of Products Under Development for Colon Cancer, H1 2013 23
Products under Development for Colon Cancer - Comparative Analysis, H1 2013 24
Number of Products under Development by Companies, H1 2013 26
Number of Products under Development by Companies, H1 2013 (Contd..1) 27
Number of Products under Development by Companies, H1 2013 (Contd..2) 28
Number of Products under Development by Companies, H1 2013 (Contd..3) 29
Number of Products under Development by Companies, H1 2013 (Contd..4) 30
Number of Products under Development by Companies, H1 2013 (Contd..5) 31
Number of Products under Development by Companies, H1 2013 (Contd..6) 32
Number of Products under Investigation by Universities/Institutes, H1 2013 34
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 35
Comparative Analysis by Late Stage Development, H1 2013 36
Comparative Analysis by Mid Clinical Stage Development, H1 2013 37
Comparative Analysis by Early Clinical Stage Development, H1 2013 38
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 39
Products under Development by Companies, H1 2013 40
Products under Development by Companies, H1 2013 (Contd..1) 41
Products under Development by Companies, H1 2013 (Contd..2) 42
Products under Development by Companies, H1 2013 (Contd..3) 43
Products under Development by Companies, H1 2013 (Contd..4) 44
Products under Development by Companies, H1 2013 (Contd..5) 45
Products under Development by Companies, H1 2013 (Contd..6) 46
Products under Development by Companies, H1 2013 (Contd..7) 47
Products under Investigation by Universities/Institutes, H1 2013 48
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 49
AstraZeneca PLC, H1 2013 50
Eli Lilly and Company, H1 2013 51
Bioniche Life Sciences, Inc., H1 2013 52
Bioneer Corporation, H1 2013 53
Prolexys Pharmaceuticals, Inc., H1 2013 54
Bio-Path Holdings, Inc., H1 2013 55
Histogen, Inc., H1 2013 56
Geistlich Pharma AG, H1 2013 57
Aphios Corporation, H1 2013 58
Alfacell Corporation, H1 2013 59
Alchemia Limited, H1 2013 60
Enzo Biochem, Inc., H1 2013 61
AEterna Zentaris Inc., H1 2013 62
ImmunoCellular Therapeutics, Ltd., H1 2013 63
Idera Pharmaceuticals, Inc., H1 2013 64
Lorus Therapeutics Inc, H1 2013 65
Bio-Bridge Science, Inc., H1 2013 66
Bionomics Limited, H1 2013 67
Cleveland BioLabs, Inc., H1 2013 68
Compugen Ltd., H1 2013 69
Patrys Limited, H1 2013 70
Critical Outcome Technologies Inc., H1 2013 71
Curis, Inc., H1 2013 72
Cytokinetics, Inc, H1 2013 73
Telik, Inc., H1 2013 74
Dendreon Corporation, H1 2013 75
Choongwae Pharma Corp, H1 2013 76
Green Cross Corporation, H1 2013 77
Innocell Corporation, H1 2013 78
Sareum Holdings plc, H1 2013 79
Transgene Biotek Ltd, H1 2013 80
Rexahn Pharmaceuticals, Inc., H1 2013 81
MabVax Therapeutics, Inc., H1 2013 82
Supratek Pharma Inc., H1 2013 83
Bionucleon Srl, H1 2013 84
Fusion Antibodies Ltd, H1 2013 85
Actinium Pharmaceuticals, Inc., H1 2013 86
Multimmune GmbH, H1 2013 87
Nerviano Medical Sciences S.r.l., H1 2013 88
Med Discovery SA, H1 2013 89
Glycotope GmbH, H1 2013 90
Archemix Corp., H1 2013 91
Provecs Medical GmbH, H1 2013 92
Coronado Biosciences, Inc., H1 2013 93
OncoMed Pharmaceuticals, Inc., H1 2013 94
Azaya Therapeutics, Inc., H1 2013 95
Deciphera Pharmaceuticals, LLC, H1 2013 96
ProNAi Therapeutics, Inc., H1 2013 97
Mersana Therapeutics, Inc., H1 2013 98
Affichem, H1 2013 99
Advenchen Laboratories, LLC, H1 2013 100
Pharminox Limited, H1 2013 101
Viral Genetics, Inc., H1 2013 102
NovaLead Pharma Pvt. Ltd., H1 2013 103
Vaccinogen, Inc., H1 2013 104
Etubics Corporation, H1 2013 105
NewLink Genetics Corporation, H1 2013 106
Cellceutix Corporation, H1 2013 107
TVAX Biomedical, LLC, H1 2013 108
CG Therapeutics, Inc., H1 2013 109
Tautatis Incorporated, H1 2013 110
Viventia Biotechnologies Inc., H1 2013 111
Merus B.V., H1 2013 112
Pique Therapeutics, H1 2013 113
Isofol Medical AB, H1 2013 114
PepTx, Inc., H1 2013 115
Celtic Pharmaceutical Holdings L.P., H1 2013 116
Gliknik, Inc., H1 2013 117
EyeGene, Inc., H1 2013 118
DEKK-TEC, Inc., H1 2013 119
ISA Pharmaceuticals B.V., H1 2013 120
TAU Therapeutics, LLC, H1 2013 121
CytomX, LLC., H1 2013 122
Assessment by Monotherapy Products, H1 2013 123
Assessment by Combination Products, H1 2013 124
Assessment by Stage and Route of Administration, H1 2013 126
Assessment by Stage and Molecule Type, H1 2013 129
Colon Cancer Therapeutics - Drug Profile Updates 304
Colon Cancer Therapeutics - Discontinued Products 329
Colon Cancer Therapeutics - Discontinued Products (Contd..1) 330
Colon Cancer Therapeutics - Dormant Products 331
Colon Cancer Therapeutics - Dormant Products (Contd..1) 332
Colon Cancer Therapeutics - Dormant Products (Contd..2) 333
Colon Cancer Therapeutics - Dormant Products (Contd..3) 334
Colon Cancer Therapeutics - Dormant Products (Contd..4) 335
Colon Cancer Therapeutics - Dormant Products (Contd..5) 336
Colon Cancer Therapeutics - Dormant Products (Contd..6) 337

List of Chart


Number of Products under Development for Colon Cancer, H1 2013 23
Products under Development for Colon Cancer - Comparative Analysis, H1 2013 24
Products under Development by Companies, H1 2013 25
Products under Investigation by Universities/Institutes, H1 2013 33
Late Stage Products, H1 2013 36
Mid Clinical Stage Products, H1 2013 37
Early Clinical Stage Products, H1 2013 38
Discovery and Pre-Clinical Stage Products, H1 2013 39
Assessment by Monotherapy Products, H1 2013 123
Assessment by Combination Products, H1 2013 124
Assessment by Route of Administration, H1 2013 125
Assessment by Stage and Route of Administration, H1 2013 126
Assessment by Molecule Type, H1 2013 127
Assessment by Stage and Molecule Type, H1 2013 128

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *